Histopathologic and molecular characterization of high-grade gliomas should now be standard practice, as specific markers used to define molecular subgroups among some anaplastic gliomas have been shown to have prognostic value. However, there are currently no targeted agents that have shown efficacy in the treatment of glioblastoma. The differential benefit from concurrent versus adjuvant temozolomide in patients with anaplastic gliomas continues to be unclear.

This tumor board will discuss how to select the most appropriate therapy for patients with lung cancer using a case-based format.

A multidisciplinary team approach involving hematology/oncology, dermatology, and radiation oncology is optimal for the management of patients with MF and SS, particularly those with advanced disease. Informing clinicians about the recommendations outlined in the NCCN Guidelines for Primary Cutaneous Lymphomas for the diagnosis and treatment of MF and SS can help them to develop an individualized treatment plan to improve quality of life and clinical outcomes.

Clinicians need to be informed about therapeutic advances and necessary supportive care precautions to aid in their effective and safe incorporation into clinical practice for the appropriate AML patient subpopulations.